Asset Allocation & Fund Positioning, Copley Fund Research

Steven Holden

Asset Allocation & Fund Positioning

Copley Fund Research

Copley Fund Research provide research and data on asset allocation among Global and Emerging Market equity funds.  The analysis details absolute and relative positioning across countries, sectors and industries together with highly granular data on single stock and single fund allocations.  The data is updated monthly with time series going back to January 2011.

Global Research - Analysis of 165 prominent Global equity funds, combined AUM $335bn
GEM Research - Analysis of 127 prominent global EM equity funds, combined AUM $250bn

Asset Allocation - Global and GEM Equity

Thematic (Sector/Industry)

<ul>
<li>Allocations in Biotechnology stocks have taken a severe drop among active China A-Share investors.  </li>
<li>From a high of 4% in July of 2020, average fund weights have fallen to just 1.14% and average underweights have plunged towards their lowest level on record.</li>
<li>
<a href="https://www.smartkarma.com/entities/wuxi-apptec" target="_blank" data-smartkarma-citation="entities:23679:1" rel="noopener">Wuxi Biologics (2269 HK)</a> has led the declines, as sentiment towards the China A-Share Biotechnology sector looks fragile.</li>
</ul>


Allocations in Biotechnology stocks have taken a severe drop among active China A-Share investors.  
From a high of 4% in July of 2020, average fund weights have fallen to just 1.14% and average underweights have plunged towards their lowest level on record.

Wuxi Biologics (2269 HK) has led the declines, as sentiment towards the China A-Share Biotechnology sector looks fragile.


Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Index Rebalance

<ul>
<li>In keeping with tradition, the SSE and CSI have continued to use a 6 month minimum listing history. No one remembers how or why it started, but it carries on.</li>
<li>There are only 10 trading days to implementation and passive funds will need to trade multiple days of ADV on the inclusions and exclusions.</li>
<li>The adds, deletes and the <a href="https://www.smartkarma.com/entities/sse-science-and-technology-innovation-board-50-index" target="_blank" data-smartkarma-citation="entities:29279:1" rel="noopener">SSE STAR50 (STAR50 INDEX)</a> have moved in lockstep since November. The CSI500 Index has outperformed over the period opening up a trading opportunity.</li>
</ul>


In keeping with tradition, the SSE and CSI have continued to use a 6 month minimum listing history. No one remembers how or why it started, but it carries on.
There are only 10 trading days to implementation and passive funds will need to trade multiple days of ADV on the inclusions and exclusions.
The adds, deletes and the SSE STAR50 (STAR50 INDEX) have moved in lockstep since November. The CSI500 Index has outperformed over the period opening up a trading opportunity.


STAR50 Index Rebalance: Index Committees Just Wanna Have Fun

China

Changchun BCHT Biotechnology Co. Ltd. operates as a high-tech biopharmaceutical company. The Company provides human vaccine researching, development, production, and sales services. Changchun BCHT Biotechnology markets its products throughout China.

Changchun BCHT Biotechnology C (688276 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Changchun BCHT Biotechnology C (688276 CH)

China A-Shares: Biotechnology Exit

Allocations in Biotechnology stocks have taken a severe drop among active China A-Share investors. From a high of 4% in July of 2020, average fund...

Steven Holden

STAR50 Index Rebalance: Index Committees Just Wanna Have Fun

The index committee has used a 6 month minimum listing history again when they should have used 12. All stocks have performed terribly & passive...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)